OUR VISION IS TO REDUCE ILLNESS AND DEATH ASSOCIATED WITH FUNGAL DISEASES WORLDWIDE.

News

Keep up to date with the latest news items from GAFFI.

First new antifungal agent – isavuconazole – launched since 2006

Posted .

This week, Isavuconazole (Cresemba) will become available in Europe for the first time, following its recent launch in the USA. This is the first new antifungal agent launched for 9 years. It has a broad spectrum, intravenous and oral formulations, is required only once daily and a very good safety profile. Following the FDA approval… Read more »

Read more >

Histoplasmosis – the leading AIDS diagnosis in the Guiana Shield and parts of central America

Posted .

  At the first ‘Histoplasmosis in the Americas and the Caribbean Meeting’ in Paramaribo Suriname, representatives from Latin America shared the dramatic problems of disseminated histoplasmosis in AIDS. The histoplasmosis problem exceeds the TB problem in many regions, and dwarfs malaria (<100 deaths annually across the Americas). One in 3 or 4 new AIDS admissions… Read more »

Read more >

World AIDS Day – progress towards the ’95-95 by 2025’ goals

Posted .

In May 2015, GAFFI issued a call to reduce AIDS deaths to under 500,000 by 2020 by provision of fungal diagnostics and antifungal therapies (GAFFI Roadmap).  In conjunction with increasing antiretroviral therapy coverage (90-90-90-  meaning action on fungal diseases will achieve a million more HIV survivors each year by 2020), diagnostics are also required for… Read more »

Read more >

Burden of fungal diseases in 636 million people in 15 countries now published

Posted .

In the Journal Mycoses, Denning and 47 co-authors from across the world have estimated the number of people affected by serious  fungal diseases in a population of 636 million in 15 countries: Belgium, Czech Republic, Denmark, Hungary, Nepal, Qatar, Tanzania, Trinidad and Tobago, Uganda, Germany, Mexico, Senegal, Tanzania, Ukraine, Vietnam. These estimates have never been attempted… Read more »

Read more >

UN 2030 Agenda for Sustainable Development – with much-needed support for reducing the impact of non-communicable diseases

Posted .

On 25th September, the UN formally adopted its 17 sustainable development goals (SDGs) and 169 targets for 2030. These goals build on and expand the Millennium Development Goals (MDG), and integrate the economic, social and environmental aspects of sustainable development. Non Communicable Diseases (NCDs) along with other major risk factors are linked to several of… Read more »

Read more >

World’s first guidelines for chronic pulmonary aspergillosis presented at ERS

Posted .

At the European Respiratory Society (ERS) Conference in Amsterdam the first world guidelines for chronic pulmonary aspergillosis have been presented by GAFFI’s president Professor Denning. The guidelines have been drawn up in conjunction with the ERS and ESCMID and will be published in the European Respiratory Journal in October. The guidelines describe the 5 clinical… Read more »

Read more >

GAFFI airs resistance and diagnostic concerns to UK China Health Dialogue

Posted .

An increased working collaboration between the UK and China was reinforced today at the UK-China Health Policy Dialogue, by Vice Premier Liu Yandong and Minister for Health Jeremy Hunt. Areas of increased co-operation included multi-level health systems support, new antimicrobial development and health infrastructure support in Africa. There was also a focus on antimicrobial resistance…. Read more »

Read more >

Allergic fungal rhinosinusitis is very common in Israel

Posted .

In Israel, 40,000 people are estimated to suffer from fungal rhinosinusitis, and unprecedented figure and the first national estimate of this problem. About 800,000 (10%) Israelis are thought to suffer from rhinitis. Fungal rhinosinusitis takes many forms and is often associated with asthma, but not always. The terminology for allergic fungal rhinosinusits is slightly confused… Read more »

Read more >

GAFFI president tours China making the case for improved fungal diagnostics

Posted .

Early in August, Professor Denning visited Lanzhou, Hangzhou, Shanghai and Guangzhou meeting clinicians, visiting laboratories and educating physicians about the large burden of fungal disease and the opportunity for improved diagnostics. He cited one example from China of the likely number of deaths from invasive aspergillosis in COPD patients. Of the estimated 32.8 million people… Read more »

Read more >